Schizophrenia

Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves.

Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms:

Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements.
"Negative" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn.
Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.

No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role.

There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training.

NIH: National Institute of Mental Health

Schizophrenia FDA Approved Drugs

ABILIFY [Aripiprazole^{C₂₃H₂₇Cl₂N₃O₂}]

10mg (oral tablet)

15mg (oral tablet)

20mg (oral tablet)

2mg (oral tablet)

30mg (oral tablet)

Otsuka^{Nov 15, 2002}

Acute treatment of manic and mixed episodes associated with bipolar i disorder.
Adjunctive treatment of major depressive disorder (mdd).
Treatment of irritability associated with autistic disorder.
Treatment of major depressive disorder (mdd).
Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder.
Treatment of schizophrenia.

efficacy
4.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

ABILIFY MAINTENA KIT [Aripiprazole^{C₂₃H₂₇Cl₂N₃O₂}]

300mg (intramuscular for suspension, extended release)

300mg/vial (intramuscular for suspension, extended release)

400mg (intramuscular for suspension, extended release)

400mg/vial (intramuscular for suspension, extended release)

Otsuka Pharm Co Ltd^{Sep 29, 2014}

Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia.
Treatment of schizophrenia.
Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia.
Use of aripiprazole in extended release injectable suspension.

efficacy
3.5 (2)

side effects
5.0 (1)

danger
1.0 (1)

ADASUVE [Loxapine^{C₁₈H₁₈ClN₃O}]

10mg (inhalation powder)

Alexza Pharms^{Dec 21, 2012}

Adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ARISTADA [Aripiprazole Lauroxil^{C₃₆H₅₁Cl₂N₃O₄}]

1064mg/3.9ml (272.82mg/ml) (intramuscular suspension, extended release)

441mg/1.6ml (275.63mg/ml) (intramuscular suspension, extended release)

662mg/2.4ml (275.83mg/ml) (intramuscular suspension, extended release)

882mg/3.2ml (275.63mg/ml) (intramuscular suspension, extended release)

Alkermes Inc^{Jun 5, 2017}

Treatment of schizophrenia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FANAPT [Iloperidone^{C₂₄H₂₇FN₂O₄}]

10mg (oral tablet)

12mg (oral tablet)

1mg (oral tablet)

4mg (oral tablet)

6mg (oral tablet)

8mg (oral tablet)

Vanda Pharms Inc^{May 6, 2009}

Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Indicated for the acute treatment of adults with schizophrenia.
Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine.
Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

INVEGA SUSTENNA [Paliperidone Palmitate^{C₃₉H₅₇FN₄O₄}]

117mg/0.75ml (117mg/0.75ml) (intramuscular suspension, extended release)

156mg/ml (156mg/ml) (intramuscular suspension, extended release)

234mg/1.5ml (156mg/ml) (intramuscular suspension, extended release)

39mg/0.25ml (39mg/0.25ml) (intramuscular suspension, extended release)

78mg/0.5ml (78mg/0.5ml) (intramuscular suspension, extended release)

Janssen Pharms^{Jul 31, 2009}

Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants.
Treatment of schizophrenia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

INVEGA TRINZA [Paliperidone Palmitate^{C₃₉H₅₇FN₄O₄}]

273mg/0.875ml (273mg/0.875ml) (intramuscular suspension, extended release)

410mg/1.315ml (311.79mg/ml) (intramuscular suspension, extended release)

546mg/1.75ml (312mg/ml) (intramuscular suspension, extended release)

819mg/2.625ml (312mg/ml) (intramuscular suspension, extended release)

Janssen Pharms^{May 18, 2015}

Treatment of schizophrenia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LATUDA [Lurasidone Hydrochloride^{C₂₈H₃₆N₄O₂SClH}]

120mg (oral tablet)

40mg (oral tablet)

60mg (oral tablet)

80mg (oral tablet)

Sunovion Pharms Inc^{Apr 26, 2012}

Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder.
Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia.
Treatment of schizophrenia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

REXULTI [Brexpiprazole^{C₂₅H₂₇N₃O₂S}]

0.25mg (oral tablet)

0.5mg (oral tablet)

1mg (oral tablet)

2mg (oral tablet)

3mg (oral tablet)

4mg (oral tablet)

Otsuka Pharm Co Ltd^{Jul 10, 2015}

Adjunctive treatment of major depressive disorder (mdd).
Treatment of schizophrenia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

SAPHRIS [Asenapine Maleate^{C₁₇H₁₆ClNOC₄H₄O₄}]

eq 10mg base (sublingual tablet)

eq 2.5 base (sublingual tablet)

eq 5mg base (sublingual tablet)

Forest Labs Llc^{Aug 13, 2009}

Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients.
Method of treating schizophrenia and bipolar disorder.
Treatment of bipolar disorder and schizophrenia.
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult).
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17.
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults.
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults.
Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

SEROQUEL XR [Quetiapine Fumarate^{2C₂₁H₂₅N₃O₂SC₄H₄O₄}]

eq 150mg base (oral tablet, extended release)

eq 200mg base (oral tablet, extended release)

eq 300mg base (oral tablet, extended release)

eq 400mg base (oral tablet, extended release)

eq 50mg base (oral tablet, extended release)

Astrazeneca^{Aug 11, 2008}

Treatment of bipolar disorder.
Treatment of major depressive disorder (mdd).
Treatment of schizophrenia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

VRAYLAR [Cariprazine Hydrochloride^{C₂₁H₃₂Cl₂N₄OClH}]

eq 1.5mg base (oral capsule)

eq 3mg base (oral capsule)

eq 4.5mg base (oral capsule)

eq 6mg base (oral capsule)

Forest Res Inst Inc^{Sep 17, 2015}

Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Schizophrenia

Schizophrenia FDA Approved Drugs